BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Guion-Dusserre JF, Lorgis V, Vincent J, Bengrine L, Ghiringhelli F. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21(7): 2096-2101 [PMID: 25717243 DOI: 10.3748/wjg.v21.i7.2096]
URL: https://www.wjgnet.com/1948-5204/full/v21/i7/2096.htm
Number Citing Articles
1
Richard Kim, E Gabriela Chiorean, Manik Amin, Caio Max S Rocha-Lima, Jitendra Gandhi, William P Harris, Tao Song, David Portnoy. Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatmentBritish Journal of Cancer 2017; 117(2): 189 doi: 10.1038/bjc.2017.160
2
Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancersWorld Journal of Gastrointestinal Oncology 2020; 12(1): 83-91 doi: 10.4251/wjgo.v12.i1.83
3
Ioannis Ntanasis-Stathopoulos, Diamantis I Tsilimigras, Maria Gavriatopoulou, Dimitrios Schizas, Timothy M Pawlik. Cholangiocarcinoma: investigations into pathway-targeted therapiesExpert Review of Anticancer Therapy 2020; 20(9): 765 doi: 10.1080/14737140.2020.1807333
4
L.-J. Palmieri, J. Lavolé, S. Dermine, C. Brezault, M. Dhooge, A. Barré, S. Chaussade, R. Coriat. The choice for the optimal therapy in advanced biliary tract cancers: Chemotherapy, targeted therapies or immunotherapyPharmacology & Therapeutics 2020; 210: 107517 doi: 10.1016/j.pharmthera.2020.107517
5
Florian Moik, Jakob M. Riedl, Thomas Winder, Angelika Terbuch, Christopher H. Rossmann, Joanna Szkandera, Thomas Bauernhofer, Anne-Katrin Kasparek, Renate Schaberl-Moser, Andreas Reicher, Felix Prinz, Martin Pichler, Herbert Stöger, Michael Stotz, Armin Gerger, Florian Posch. Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysisScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-42069-1
6
Pamela Minicozzi, Tiziana Cassetti, Claudia Vener, Milena Sant. Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimatesCancer Epidemiology 2018; 55: 52 doi: 10.1016/j.canep.2018.04.011
7
Jie Ying, Jinfei Chen. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published dataCritical Reviews in Oncology/Hematology 2019; 139: 134 doi: 10.1016/j.critrevonc.2019.01.001
8
G. Lurje, J. Bednarsch, C. Roderburg, C. Trautwein, U. P. Neumann. Aktueller Therapiealgorithmus des intrahepatischen cholangiozellulären KarzinomsDer Chirurg 2018; 89(11): 858 doi: 10.1007/s00104-018-0718-y
9
Nicolas Roussot, Julie Vincent, Remi Palmier, Guillaume Constantin, Leila Bengrine, Jean-David Fumet, François Ghiringhelli. FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapyFrontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1293670
10
Li-Ye Wang, Shuai Gong, Li-Ping Gao, Li-Xia Hou, Wei He. Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapyMedicine 2018; 97(49): e13372 doi: 10.1097/MD.0000000000013372
11
M. Tampellini, A. La Salvia, G. V. Scagliotti. Novel investigational therapies for treating biliary tract carcinomaExpert Opinion on Investigational Drugs 2016; 25(12): 1423 doi: 10.1080/13543784.2016.1252330
12
Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract CancerTargeted Oncology 2023; 18(6): 837 doi: 10.1007/s11523-023-01000-5
13
Nicholas Holt, Joanna Lee, Ngee Soon Lau, Natalie Collier, Oliver M. Fisher, Carlo Pulitano, Katrin Sjoquist, Craig Philip I.. Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e2024; : 407 doi: 10.1002/9781119756422.ch21
14
Maria Maddalena Simile, Paola Bagella, Gianpaolo Vidili, Angela Spanu, Roberto Manetti, Maria Antonietta Seddaiu, Sergio Babudieri, Giordano Madeddu, Pier Andrea Serra, Matteo Altana, Panagiotis Paliogiannis. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical TrialsMedicina 2019; 55(2): 42 doi: 10.3390/medicina55020042
15
Amit Mahipal, Anuhya Kommalapati, Sri Harsha Tella, Alexander Lim, Richard Kim. Novel targeted treatment options for advanced cholangiocarcinomaExpert Opinion on Investigational Drugs 2018; 27(9): 709 doi: 10.1080/13543784.2018.1512581
16
Valeria Simone, Oronzo Brunetti, Luigi Lupo, Mario Testini, Eugenio Maiorano, Michele Simone, Vito Longo, Christian Rolfo, Marc Peeters, Aldo Scarpa, Amalia Azzariti, Antonio Russo, Domenico Ribatti, Nicola Silvestris. Targeting Angiogenesis in Biliary Tract Cancers: An Open OptionInternational Journal of Molecular Sciences 2017; 18(2): 418 doi: 10.3390/ijms18020418
17
Pedro Luiz Serrano Uson Junior, Tanios Bekaii-Saab. Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?Immunotherapy 2023; 15(7): 531 doi: 10.2217/imt-2022-0201
18
Giovanni Brandi, Michela Venturi, Maria Abbondanza Pantaleo, Giorgio Ercolani, Lorenzo Fornaro, Nicola Silvestris, Francesco Leone, Enrico Vasile, Sara Lonardi, Stefano Cereda, Daniele Santini, Giuseppe Aprile. Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithmsDigestive and Liver Disease 2016; 48(3): 231 doi: 10.1016/j.dld.2015.11.017
19
Brinda Balasubramanian, Simran Venkatraman, Kyaw Zwar Myint, Tavan Janvilisri, Kanokpan Wongprasert, Supeecha Kumkate, David O. Bates, Rutaiwan Tohtong. Co-Clinical Trials: An Innovative Drug Development Platform for CholangiocarcinomaPharmaceuticals 2021; 14(1): 51 doi: 10.3390/ph14010051
20
Philipp Heumann, Andreas Albert, Karsten Gülow, Denis Tümen, Martina Müller, Arne Kandulski. Current and Future Therapeutic Targets for Directed Molecular Therapies in CholangiocarcinomaCancers 2024; 16(9): 1690 doi: 10.3390/cancers16091690
21
José María Huguet, Miriam Lobo, José Mir Labrador, Carlos Boix, Cecilia Albert, Luis Ferrer-Barceló, Ana B Durá, Patricia Suárez, Isabel Iranzo, Mireia Gil-Raga, Celia Baez de Burgos, Javier Sempere. Diagnostic-therapeutic management of bile duct cancerWorld Journal of Clinical Cases 2019; 7(14): 1732-1752 doi: 10.12998/wjcc.v7.i14.1732
22
Leonard M. Quinn, Nicholas Bird, Robert Jones, David Vass, Hassan Malik. Liver Cancers2019; : 199 doi: 10.1007/978-3-319-92216-4_16
23
Anwaar Saeed, Robin Park, Mohammed Al-Jumayli, Raed Al-Rajabi, Weijing Sun. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced CholangiocarcinomaClinical Colorectal Cancer 2019; 18(2): 81 doi: 10.1016/j.clcc.2019.02.005
24
Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancersWorld Journal of Gastrointestinal Oncology 2020; 12(1): 83-91 doi: 10.4251/wjgo.v12.i1.83
25
Grégoire Marret, Cindy Neuzillet, Benoît Rousseau, Christophe Tournigand. Traitements médicaux des cholangiocarcinomes en 2015Bulletin du Cancer 2016; 103(4): 389 doi: 10.1016/j.bulcan.2016.01.019
26
Margherita Rimini, Andrea Casadei-Gardini. Angiogenesis in biliary tract cancer: targeting and therapeutic potentialExpert Opinion on Investigational Drugs 2021; 30(4): 411 doi: 10.1080/13543784.2021.1881479
27
Luca Maroni, Marco Marzioni. Diagnosis and Management of Cholangiocarcinoma2021; : 555 doi: 10.1007/978-3-030-70936-5_26
28
Yong-Na Wu, Li-Hong He, Zhong-Tian Bai, Xun Li. <p>NRP1 is a Prognostic Factor and Promotes the Growth and Migration of Cells in Intrahepatic Cholangiocarcinoma</p>Cancer Management and Research 2020; : 7021 doi: 10.2147/CMAR.S260091
29
Pashtoon Murtaza Kasi. Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid BiopsiesCase Reports in Oncology 2020; 13(2): 941 doi: 10.1159/000509075
30
Cindy Neuzillet, Benoît Rousseau, Hemant Kocher, Philippe Bourget, Christophe Tournigand. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomasPharmacology & Therapeutics 2017; 174: 145 doi: 10.1016/j.pharmthera.2017.02.028
31
Wei Zhang, Hongyuan Zhou, Yingying Wang, Zewu Zhang, Guangtai Cao, Tianqiang Song, Ti Zhang, Qiang Li. Systemic treatment of advanced or recurrent biliary tract cancerBioScience Trends 2020; 14(5): 328 doi: 10.5582/bst.2020.03240
32
Concetta Elisa Onesti, Adriana Romiti, Michela Roberto, Rosa Falcone, Paolo Marchetti. Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failureExpert Review of Anticancer Therapy 2015; 15(10): 1183 doi: 10.1586/14737140.2015.1081816
33
Margherita Rimini, Marco Puzzoni, Federica Pedica, Nicola Silvestris, Lorenzo Fornaro, Giuseppe Aprile, Eleonora Loi, Oronzo Brunetti, Caterina Vivaldi, Francesca Simionato, Patrizia Zavattari, Mario Scartozzi, Valentina Burgio, Francesca Ratti, Luca Aldrighetti, Stefano Cascinu, Andrea Casadei-Gardini. Cholangiocarcinoma: new perspectives for new horizonsExpert Review of Gastroenterology & Hepatology 2021; 15(12): 1367 doi: 10.1080/17474124.2021.1991313
34
Angélique Vienot, Cindy Neuzillet. Continuum of care for advanced biliary tract cancersClinics and Research in Hepatology and Gastroenterology 2020; 44(6): 810 doi: 10.1016/j.clinre.2020.05.009
35
Gabriel Allo, Ahu Can, Roger Wahba, Nils Vogel, Tobias Goeser, Fabian Kütting, Dirk Waldschmidt. Nanoliposomal irinotecan in combination with leucovorin and 5‑fluorouracil in advanced biliary tract cancersMolecular and Clinical Oncology 2021; 16(2) doi: 10.3892/mco.2021.2485
36
L. Perkhofer, A. W. Berger, A. K. Beutel, E. Gallmeier, S. Angermeier, L. Fischer von Weikersthal, T. O. Goetze, R. Muche, T. Seufferlein, T. J. Ettrich. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II studyBMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6142-y
37
Marc Hilmi, Angélique Vienot, Benoît Rousseau, Cindy Neuzillet. Immune Therapy for Liver CancersCancers 2019; 12(1): 77 doi: 10.3390/cancers12010077
38
Sri Harsha Tella, Anuhya Kommalapati, Mitesh J Borad, Amit Mahipal. Second-line therapies in advanced biliary tract cancersThe Lancet Oncology 2020; 21(1): e29 doi: 10.1016/S1470-2045(19)30733-8
39
Roberto Filippi, Pasquale Lombardi, Virginia Quarà, Elisabetta Fenocchio, Giacomo Aimar, Michela Milanesio, Francesco Leone, Massimo Aglietta. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectivesExpert Opinion on Pharmacotherapy 2019; 20(17): 2121 doi: 10.1080/14656566.2019.1667335
40
Linde Kehmann, Marie-Luise Berres, Maria Gonzalez-Carmona, Dominik P. Modest, Raphael Mohr, Alexander Wree, Marino Venerito, Christian Strassburg, Verena Keitel, Christian Trautwein, Tom Luedde, Christoph Roderburg. Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-10972-6
41
Jennifer Yang, Matthew R. Farren, Daniel Ahn, Tanios Bekaii-Saab, Gregory B. Lesinski. Signaling pathways as therapeutic targets in biliary tract cancerExpert Opinion on Therapeutic Targets 2017; 21(5): 485 doi: 10.1080/14728222.2017.1306055
42
Lorenzo Fornaro, Caterina Vivaldi, Stefano Cereda, Francesco Leone, Giuseppe Aprile, Sara Lonardi, Nicola Silvestris, Daniele Santini, Michele Milella, Chiara Caparello, Gianna Musettini, Giulia Pasquini, Alfredo Falcone, Giovanni Brandi, Isabella Sperduti, Enrico Vasile. Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published dataJournal of Experimental & Clinical Cancer Research 2015; 34(1) doi: 10.1186/s13046-015-0267-x
43
John R. Bergquist, Tommy Ivanics, Curtis B. Storlie, Ryan T. Groeschl, May C. Tee, Elizabeth B. Habermann, Rory L. Smoot, Michael L. Kendrick, Michael B. Farnell, Lewis R. Roberts, Gregory J. Gores, David M. Nagorney, Mark J. Truty. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysisJournal of Surgical Oncology 2016; 114(4): 475 doi: 10.1002/jso.24381
44
Ester Oneda, Mohammed Abu Hilal, Alberto Zaniboni. Biliary Tract Cancer: Current Medical Treatment StrategiesCancers 2020; 12(5): 1237 doi: 10.3390/cancers12051237
45
Abdullah Esmail, Mohamed Badheeb, Batool Wael Alnahar, Bushray Almiqlash, Yara Sakr, Ebtesam Al-Najjar, Ali Awas, Mohammad Alsayed, Bayan Khasawneh, Mohammed Alkhulaifawi, Amneh Alsaleh, Ala Abudayyeh, Yaser Rayyan, Maen Abdelrahim. The Recent Trends of Systemic Treatments and Locoregional Therapies for CholangiocarcinomaPharmaceuticals 2024; 17(7): 910 doi: 10.3390/ph17070910
46
Fabiana Crispo, Michele Pietrafesa, Valentina Condelli, Francesca Maddalena, Giuseppina Bruno, Annamaria Piscazzi, Alessandro Sgambato, Franca Esposito, Matteo Landriscina. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future PerspectivesMolecules 2020; 25(16): 3754 doi: 10.3390/molecules25163754
47
Urvi A. Shah, Amara G. Nandikolla, Lakshmi Rajdev. Immunotherapeutic Approaches to Biliary CancerCurrent Treatment Options in Oncology 2017; 18(7) doi: 10.1007/s11864-017-0486-9
48
Audrey E Kam, Ashiq Masood, Rachna T Shroff. Current and emerging therapies for advanced biliary tract cancersThe Lancet Gastroenterology & Hepatology 2021; 6(11): 956 doi: 10.1016/S2468-1253(21)00171-0
49
Aram A. Musaelyan, Ekaterina M. Anokhina, Alina I. Turdubaeva, Natalia V. Mitiushkina, Anastasia N. Ershova, Anna D. Shestakova, Aigul R. Venina, Evgeny N. Imyanitov, Sergey V. Orlov. Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman with NRAS-mutated metastatic intrahepatic cholangiocarcinoma: a case reportExploration of Targeted Anti-tumor Therapy 2024; 5(3): 780 doi: 10.37349/etat.2024.00246
50
Changqing Xie, Nicole A. McGrath, Cecilia Monge Bonilla, Jianyang Fu. Systemic treatment options for advanced biliary tract carcinomaJournal of Gastroenterology 2020; 55(10): 944 doi: 10.1007/s00535-020-01712-9
51
Adriana Romanzi, Erica Villa. Angiogenesis: the Yin and Yang in intrahepatic cholangiocarcinomaHepatoma Research 2023;  doi: 10.20517/2394-5079.2023.53
52
Aslam Ejaz, Jordan M. Cloyd, Timothy M. Pawlik. Advances in the Diagnosis and Treatment of Patients with Intrahepatic CholangiocarcinomaAnnals of Surgical Oncology 2020; 27(2): 552 doi: 10.1245/s10434-019-07873-z
53
Loic Verlingue, Antoine Hollebecque, Valérie Boige, Michel Ducreux, David Malka, Charles Ferté. Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?European Journal of Cancer 2017; 81: 161 doi: 10.1016/j.ejca.2017.05.006
54
Jang Han Jung, Hee Seung Lee, Jung Hyun Jo, In Rae Cho, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jeong Youp Park. Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract CancerChemotherapy 2017; 62(6): 361 doi: 10.1159/000479425